| P2093 | author name string | Mark J Millan | |
| P2860 | cites work | Finding the missing heritability of complex diseases | Q22122198 |
| | Trace amine-associated receptors as emerging therapeutic targets | Q22242286 |
| | 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia | Q24299992 |
| | Tricyclic antidepressant pharmacology and therapeutic drug interactions updated | Q24564967 |
| | A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder | Q24602988 |
| | mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade | Q24617166 |
| | A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder | Q24624059 |
| | Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans | Q24627318 |
| | Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity | Q24642035 |
| | Trace amine-associated receptor 1 as a monoaminergic modulator in brain | Q24650242 |
| | The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress | Q24650789 |
| | Ketamine for treatment-resistant unipolar depression: current evidence | Q27004508 |
| | Systems genetics for drug target discovery | Q27012769 |
| | Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents | Q28140526 |
| | Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial | Q28248361 |
| | Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent | Q28253110 |
| | Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression | Q28253233 |
| | S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization | Q28255656 |
| | Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders | Q28263028 |
| | Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline | Q28274642 |
| | In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor | Q28281128 |
| | MCL0042: a nonpeptidic MC4 receptor antagonist and serotonin reuptake inhibitor with anxiolytic- and antidepressant-like activity | Q28285653 |
| | Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment | Q28285951 |
| | Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies | Q28293380 |
| | Can we rationally design promiscuous drugs? | Q28294268 |
| | Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application | Q28300751 |
| | Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs | Q28305100 |
| | Potentially inappropriate use of psychotropic medications in hospitalized elderly patients in France: cross-sectional analysis of the prospective, multicentre SAFEs cohort | Q37306775 |
| | Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic | Q37356659 |
| | Epigenetic dysregulation in cognitive disorders. | Q37512513 |
| | Tachykinin receptor antagonists in clinical trials | Q37638682 |
| | Polypharmacy in schizophrenia | Q37669107 |
| | Mechanism of action of trazodone: a multifunctional drug | Q37679880 |
| | Exploration of structure-activity relationships for dual serotonin transporter reuptake inhibitors-histamine H3 receptor antagonists | Q37694645 |
| | The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action | Q37695716 |
| | Efficacy of the sequential integration of psychotherapy and pharmacotherapy in major depressive disorder: a preliminary meta-analysis | Q37742790 |
| | Sleep deprivation in depression | Q37768442 |
| | If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies | Q37822778 |
| | Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings | Q37826637 |
| | Epigenetic treatments for cognitive impairments | Q37877119 |
| | Genes, environment, and individual differences in responding to treatment for depression | Q37883317 |
| | Vilazodone: in major depressive disorder | Q37893639 |
| | Rapid-acting antidepressant strategies: mechanisms of action | Q37898216 |
| | Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action | Q37928965 |
| | Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. | Q37945726 |
| | Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics | Q37958581 |
| | MicroRNAs and depression | Q37973957 |
| | The hidden third: improving outcome in treatment-resistant depression | Q37974998 |
| | Can we discover pharmacological promiscuity early in the drug discovery process? | Q37978022 |
| | Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia | Q37979282 |
| | Emerging targets for the pharmacological treatment of depression: focus on melatonergic system | Q37984116 |
| | Emerging drugs for major depressive disorder | Q37984619 |
| | The role of transcranial magnetic stimulation in treatment-resistant depression: a review | Q38017263 |
| | Mindfulness-based stress reduction, mindfulness-based cognitive therapy, and Zen meditation for depression, anxiety, pain, and psychological distress | Q38027032 |
| | Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. | Q38036613 |
| | 5-HT2 ligands in the treatment of anxiety and depression | Q38037141 |
| | An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy | Q38068037 |
| | Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study | Q38465810 |
| | The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder | Q38480752 |
| | Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial | Q39557334 |
| | Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor | Q40086313 |
| | Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. | Q40496424 |
| | SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test | Q42171505 |
| | Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. | Q42613197 |
| | S41744, a dual neurokinin (NK)1 receptor antagonist and serotonin (5-HT) reuptake inhibitor with potential antidepressant properties: a comparison to aprepitant (MK869) and paroxetine | Q43059758 |
| | Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm | Q43199179 |
| | WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity | Q43261403 |
| | Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats | Q43548242 |
| | Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties | Q43550020 |
| | NPY intraperitoneal injections produce antidepressant-like effects and downregulate BDNF in the rat hypothalamus | Q44381668 |
| | Enhancement of antidepressant potency by a potentiator of AMPA receptors | Q44490783 |
| | A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease | Q44586144 |
| | Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. | Q44591135 |
| | Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response | Q44793035 |
| | Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders | Q28307264 |
| | mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists | Q29618120 |
| | Metabotropic glutamate receptors: from the workbench to the bedside | Q30448778 |
| | Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models | Q30466695 |
| | Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy | Q30468153 |
| | Cognitive enhancing effects of ghrelin receptor agonists | Q30968658 |
| | Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. | Q33288908 |
| | From synapse to nucleus: novel targets for treating depression | Q33653177 |
| | Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials | Q33980006 |
| | Medication augmentation after the failure of SSRIs for depression. | Q33994373 |
| | A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder | Q34031897 |
| | NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders | Q34050607 |
| | Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. | Q34088016 |
| | National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 |
| | Agomelatine, the first melatonergic antidepressant: discovery, characterization and development | Q34122643 |
| | Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients | Q34124551 |
| | Overview of the Genetics of Major Depressive Disorder | Q34138509 |
| | MicroRNA in the regulation and expression of serotonergic transmission in the brain and other tissues | Q34166428 |
| | Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis | Q34172837 |
| | Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder | Q34226609 |
| | The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression | Q34234098 |
| | Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). | Q34235666 |
| | S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. | Q34241332 |
| | Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression | Q34242827 |
| | α7-Nicotinic receptors and cognition | Q34251400 |
| | Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. | Q34282033 |
| | The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine | Q34496400 |
| | A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants | Q34594119 |
| | Serotonin receptors, type 4: a new hope? | Q34611128 |
| | Therapeutic options for treatment-resistant depression | Q34615947 |
| | Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. | Q34634320 |
| | Activation of the mGlu7 receptor elicits antidepressant-like effects in mice | Q34648343 |
| | Modafinil: a review of neurochemical actions and effects on cognition | Q34665871 |
| | Which antidepressants have demonstrated superior efficacy? A review of the evidence | Q34698836 |
| | Immune system to brain signaling: neuropsychopharmacological implications. | Q34769827 |
| | WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent | Q34771625 |
| | The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. | Q34775163 |
| | S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models | Q34784727 |
| | Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression | Q34797287 |
| | Antidepressant actions of histone deacetylase inhibitors | Q35003394 |
| | Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders | Q35143623 |
| | The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder | Q35159668 |
| | Selective p38α MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction | Q35163121 |
| | Functional biomarkers of depression: diagnosis, treatment, and pathophysiology | Q35356872 |
| | Antidepressant-like effect induced by systemic and intra-hippocampal administration of DNA methylation inhibitors. | Q35593084 |
| | Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial | Q35689739 |
| | Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents | Q35754079 |
| | Brain-derived neurotrophic factor and neuropsychiatric disorders | Q35847085 |
| | Ketamine for depression: where do we go from here? | Q36223372 |
| | Polytherapy in bipolar disorder | Q36361982 |
| | Pindolol augmentation of antidepressant response | Q36395646 |
| | Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter | Q36407799 |
| | Efficacy of light therapy for perinatal depression: a review | Q36455917 |
| | Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice | Q36603189 |
| | Multi-target therapeutics: when the whole is greater than the sum of the parts | Q36697412 |
| | Fragments, network biology and designing multiple ligands | Q36727203 |
| | A preclinical and clinical rationale for quetiapine in mood syndromes | Q36847279 |
| | Characterization of the potent 5-HT(1A/B) receptor antagonist and serotonin reuptake inhibitor SB-649915: preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy. | Q36879560 |
| | From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. | Q37090054 |
| | Glucocorticoid antagonists in neuropsychiatric [corrected] disorders | Q37109672 |
| | Circadian abnormalities, molecular clock genes and chronobiological treatments in depression | Q37167041 |
| | Preclinical characterization of WAY-211612: a dual 5-HT uptake inhibitor and 5-HT (1A) receptor antagonist and potential novel antidepressant | Q37230927 |
| | Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter | Q37232938 |
| | 5-HT1 receptor augmentation strategies as enhanced efficacy: therapeutics for psychiatric disorders | Q37239942 |
| | Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138. | Q37248875 |
| | Genetic and epigenetic defects in mental retardation. | Q37259024 |
| | Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms | Q37266134 |
| | Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain | Q45072878 |
| | Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study | Q45851034 |
| | Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. | Q46027622 |
| | 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor | Q46300085 |
| | Antidepressant-like effect of 17beta-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems | Q46326898 |
| | Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization | Q46335868 |
| | Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists | Q46365816 |
| | The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug | Q46782301 |
| | Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis | Q46848261 |
| | Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds | Q46903303 |
| | Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors | Q48099473 |
| | Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its a | Q48103864 |
| | Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis | Q48291954 |
| | Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor | Q48292564 |
| | Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. | Q48319504 |
| | Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice | Q48385448 |
| | Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. | Q48475829 |
| | Aberrant epigenetic landscape in intellectual disability. | Q48543830 |
| | Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice | Q48554397 |
| | Serum ghrelin levels and the effects of antidepressants in major depressive disorder and panic disorder | Q48617387 |
| | Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex | Q48656974 |
| | Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study | Q48695277 |
| | The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling | Q48793282 |
| | Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. | Q48801789 |
| | Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus | Q48818809 |
| | Transcranial direct current stimulation for the outpatient treatment of poor-responder depressed patients. | Q48860880 |
| | Fluoxetine, 17-β estradiol or folic acid combined with intra-lateral septal infusions of neuropeptide Y produced antidepressant-like actions in ovariectomized rats forced to swim | Q48861953 |
| | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. | Q48866754 |
| | Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 |
| | Intra-lateral septal infusions of folic acid alone or combined with various antidepressant drugs produce antidepressant-like actions in male Wistar rats forced to swim | Q48906746 |
| | Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel α₂-adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine | Q49083634 |
| | ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. | Q51700487 |
| | Is pharma running out of brainy ideas? | Q51847289 |
| | Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism | Q58136475 |
| | The physicochemical challenges of designing multiple ligands | Q80048530 |
| | Depression drug disappoints | Q82559540 |
| | Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study | Q83294329 |
| | Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test | Q83975409 |
| | Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder | Q84586878 |
| P433 | issue | 7 | |
| P304 | page(s) | 1009-1037 | |
| P577 | publication date | 2013-05-30 | |
| P1433 | published in | The International Journal of Neuropsychopharmacology | Q7742309 |
| P1476 | title | On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal | |
| P478 | volume | 17 | |